1. INTRODUCTION {#sec1}
===============

Mortality due to stroke has been declining over the past decades, most likely due to better management of vascular risk factors \[[@r1]\]. However, patients with dementia may be at a higher risk of dying from stroke \[[@r2]\]. Moreover, patients with dementia receive less intensive health care and they may not be appropriately managed for their cardiovascular comorbidities \[[@r3]-[@r5]\].

In the general population, stroke is the leading cause of death among older women and the second most frequent cause of death in Sweden overall \[[@r6]\]. In patients with dementia, the most common causes of death are bronchopneumonia and cardiovascular disease while death from neoplastic diseases is less common compared to the general older population \[[@r2], [@r7]-[@r10]\].

The severity of dementia may also influence the cause of death. While bronchopneumonia occurred more often in severely affected Alzheimer\'s disease (AD) patients, heart disease, stroke and other common causes of death predominated in less cognitively impaired patients \[[@r11]\]. In a recent study from SveDem stroke was a cause of death in 18.6% \[[@r10]\]. Dementia type is associated with cause of death - cerebrovascular diseases (CVD) are a significantly more common cause of death in vascular dementia \[[@r10], [@r12]\] patients compared to AD patients (33.3% *vs.* 9.3%) \[[@r10], [@r13]\]. However, most previous studies focused exclusively on AD patients and less information exists on stroke as a cause of death in other dementia types.

Death certificates are widely used in ascertainment of cause of death \[[@r14], [@r15]\]. Although their quality has been questioned, particularly in older individuals \[[@r15]\], a recent study with Swedish death certificates found an agreement of 87-88% for cardiovascular causes of death at the 3-digit level of the ICD-10 \[[@r16]\]. Swedish quality registers have a long tradition for improving quality of care and are often used in research. In a previous study from the Swedish Dementia Registry (SveDem), we examined the causes of death from death certificates according to dementia type and underlying demographic factors \[[@r10]\]. Now, we propose a study focusing on ischemic stroke (IS), with the aim to describe the characteristics of patients with dementia dying from stroke and to determine what proportion of patients with a stroke in their death certificate had been diagnosed with stroke before death. A cross-reference with the Swedish Stroke Register \[[@r17]\] was performed to determine whether individuals received a stroke diagnosis before the terminal event, in an effort to increase the reliability of the death certificate diagnoses. Lastly, we aimed to establish whether the place of death contributed to missing clinical stroke diagnoses in patients dying from stroke according to their death certificates.

2. MATERIALS AND METHODS {#sec2}
========================

A retrospective analysis of prospectively collected data of patients registered in the quality Swedish Dementia Registry (SveDem) was conducted. Information about the causes of death was acquired from the Swedish Death Register, about comorbidities from the Swedish Patient Register and about drugs from the Swedish Prescribed Drugs Register. Patients and their relatives were informed of the entry into SveDem and could decline participation or have their data removed at any time. Data were de-identified before analysis. This study complies with the Declaration of Helsinki and was approved by the regional ethical review board in Stockholm, Sweden (dnr 2015/743-31/4).

2.1. Source of Data {#sec2.1}
-------------------

The Swedish Dementia Registry (SveDem) was established in May 2007, with the aim to monitor the care of patients with dementia in Sweden, as previously described in detail \[[@r18]\]. Patients with dementia are registered at the time of their dementia diagnosis by physicians in memory clinics or primary care units. Diagnoses were made according to the International Classification of Diseases version 10 (ICD-10) criteria, \[[@r19]\] with specific criteria used for the different dementia types. The following dementia disorders are included in SveDem and were considered for this study: Alzheimer\'s dementia (AD), vascular dementia \[[@r12]\], mixed AD and VD (mixed), dementia with Lewy bodies (DLB), frontotemporal dementia (FTD), Parkinson\'s disease dementia (PDD) and unspecified dementia (UD). Information on age, sex, Mini-Mental State Examination (MMSE) score, use of medication and living conditions are recorded. In the present study, we use data of patients that were registered between 2007 and 2014.

Data on death were obtained from death certificates collected in the Swedish Death Register until December 2014. IS was included as the cause of death if it was mentioned either as the main or contributory cause (ICD-10 code I63). All other causes of death were included in the variable "dead from other causes". The Swedish Stroke Registry covers all Swedish hospitals involved in acute stroke with a coverage \>90% for IS events \[[@r17]\] and was used to ascertain stroke diagnoses \[[@r20]\]. Stroke events occurring between 2007 and 2014 were included. Deaths were attributed to stroke if the death certificate contained stroke as the cause of death and the patient had a stroke registered in Riksstroke within 1 year prior to death. The place of death was either hospital, nursing home or at home.

Information on comorbidities was obtained from the Swedish Patient Registry that covers all hospital and specialist care in Sweden \[[@r21]\]. One main diagnosis and up to 21 additional diagnoses are registered with ICD 10 codes. In the present study, we considered a comorbidity present if the code appeared at least once as the main or additional diagnosis from 1998 until the end of 2014. We used the following codes for comorbidities: diabetes mellitus (E10-E13), arterial hypertension (I10-I15), anemia (D50 and D62), liver diseases (K70-77), kidney diseases (N10-19), heart failure (I50), atrial fibrillation (I48), previous femur fracture (S72), previous stroke (I64, I63, I60-I62).

Information on drug use was obtained from the Prescribed Drugs Registry which contains information on all dispensed prescriptions since July 2005 at Swedish pharmacies to the entire Swedish population \[[@r22]\]. Drugs are coded according to the Anatomical Therapeutic Chemical (ATC) Classification system. In the present study, we analyzed drugs dispensed at the time of dementia diagnoses and up to 3 years prior to this date, using the following codes: antidiabetic drugs (A10), antithrombotic agents (B01), diuretics (C03), beta blocking agents (C07), calcium-channel blockers (C08), agents acting on the renin-angiotensin system (C09), lipid-modifying agents (C10), antipsychotics (N05A), antidepressants (N06A), cholinesterase inhibitors (ChEIs) (N06DA), memantine (N06DX01), anxiolytics (N05B), hypnotics and sedatives (N05C). The use of sleeping aids was obtained from SveDem since ATC codes do not always reveal the intention of the prescription. Further, we consider the total number of medication at the time of dementia diagnosis as a proxy for overall co-morbidity.

2.2. Statistical Analyses {#sec2.2}
-------------------------

Data is described as means ± standard deviation (SD), median and interquartile range (IQR) or frequency (number-n and percentage-%), where appropriate. Baseline characteristics of the patients at the time of dementia diagnosis were compared between patients dying from IS and registered in Riksstroke, patients dying from IS without being registered in Riksstroke and those dying from other causes using chi-square test or T-test, as appropriate. Age was compared using ANOVA with the Welch test because of non-homogenous variances and the total number of drugs using the Kruskal-Wallis test. Logistic regression was used to assess the association of place of death (hospital, nursing home or at home) with IS in the death certificate and having a Riksstroke registration. The final models were adjusted for age, sex, number of medication, MMSE, dementia type, previous diagnosis of diabetes, hypertension, heart failure, atrial fibrillation, stroke, anemia, hip fracture, liver diseases and kidney diseases. Adjusted odds ratios (ORs) with 95% confidence intervals (CIs) are presented.

Two-tailed P \< 0.05 was considered to be statistically significant in all analytical procedures. Data were analysed using the Statistical Package for the Social Sciences software version 22 (IBM Corporation, Armonk, NY, USA).

3. RESULTS {#sec3}
==========

Out of 49823 patients diagnosed with dementia between 2007 and 2014 in primary care or specialist clinics, 14170 (28.4%) had died by the end of 2014. Of these, 1180 (8.3%) had IS mentioned in their death certificate, of which 459 (38.9%) had also been registered in Riksstroke for a stroke event in the year preceding death. Characteristics of the cohort are presented in Table **[1](#T1){ref-type="table"}**. Of patients who died of IS, there were additionally 153 patients who had a Riksstroke registration more than a year preceding death, totaling 612 patients with a confirmed IS or 52% of those with IS mentioned on their death certificates. Characteristics of this cohort are presented in Supplemental Table **1**.

Among patients who died of IS, the most common type of dementia was VD, while those dead from other causes were most often diagnosed with AD. Patients who died from IS and were registered in Riksstroke had higher MMSE score compared to other groups (21.0 *vs.* 20.0 *vs.* 20.0; p\<0.001).

56.0% of patients died from IS and registered in Riksstroke died in hospital compared to 16.8% patients who died from IS without being registered in Riksstroke, and 25.1% who died from other causes. Patients who died from IS were slightly older when registered in SveDem, but in all groups patients died with a mean age of 84 years.

Patients who died from IS took more medications at the time of dementia diagnosis, when compared to patients who died from other causes (6.0 *vs.* 5.0; p\<0.001). Specifically, they were prescribed more cardiovascular drugs, such as antithrombotic agents, beta-blockers, agents acting on the renin-angiotensin system, lipid-modifying agents and antidiabetics. There were no statistically significant differences in the use of antipsychotics, antidepressants, ChEIs, memantine, anxiolytics, or hypnotics between the groups. Fig. (**[1](#F1){ref-type="fig"}**) shows medication use at the time of dementia diagnosis in patients who died from IS and those who died from other causes.

Dying in a hospital was associated with increased odds of having a stroke in the death certificate and being registered in Riksstroke (Table **[3](#T3){ref-type="table"}**). Compared to patients dying in a hospital, those dying in a nursing home had lower odds of having IS in their death certificates (OR 0.80, 95% CI 0.69-0.92) and, among those dying from IS, nursing home residents were less likely to present a Riksstroke registration within one year of death (OR 0.17, 95% CI 0.12-0.22).

4. DISCUSSION {#sec4}
=============

There were 8% of patients with dementia in our study who died from IS, which is slightly higher than the 6% that die from IS in the general population \[[@r23]\]. Some studies evaluated stroke as a cause of death in dementia patients \[[@r2], [@r7], [@r8], [@r11], [@r13]\] providing conflicting results. Some showed that death because of CVD was more common in dementia patients than in the general population \[[@r2]\] while others did not demonstrate a difference, \[[@r8]\] or showed the opposite results \[[@r7]\]. Death from CVD accounted for around 4-13% of all deaths in patients with dementia in different studies \[[@r2], [@r7]\].

In our cohort, only one-third of all patients who died of IS had been registered in Riksstroke for a stroke event in the year preceding death. There are a few possible explanations for this low number of registrations in Riksstroke. First, it is estimated that around 10% of strokes may be missed by Riksstroke (90% coverage) \[[@r17]\]. Further, some patients with strokes may survive more than one year from the stroke event and would have been excluded from this study: in these cases, however, it may be hard to attribute the death to stroke. Therefore we performed a secondary analysis including all patients with previous Riksstroke registration irrespective of the time between stroke and death. This increased the percentage of patients with an established stroke diagnosis to 52% but did not change the findings of previous analysis (Supplemental Table **1, 2, 3**). In a previous study examining mortality after IS, the highest mortality rate occurred in the first 3 months after IS but remained elevated even among patients who survived 2 years \[[@r24]\] . In the first month after IS, deaths were caused primarily by neurologic complications of brain ischemia, while later deaths were mostly associated with cardiac and pulmonary events \[[@r24]\]. Similarly, another study examining long-term survival after stroke found that stroke was associated with an almost 5-fold increase in risk for death between one month and one year after the first stroke and a 2-fold increase after 1 year compared with the general population. In this study, almost half of the patients died one year after the stroke \[[@r25]\]. In another study that examined early and long-term causes of death after IS, stroke caused early deaths in 57% and only 14% long-term deaths \[[@r26]\].

Another important point is the accuracy of death certificate diagnosis. Different definitions of stroke as a cause of death in literature make comparisons between studies challenging. Beside this, it is well-known among clinicians that the diagnosis of stroke in a patient with severe dementia is complicated due to impaired communication and cooperation at examination \[[@r27]\]. However, generally high error rates appeared in death certification - approximately 33-41% of
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incorrectly identified causes of death, with disproportionate overrepresentation of cardiovascular events \[[@r28]\]. For example, data from the Framingham Heart Study suggests that cardiovascular causes of death are overstated in at least 24% of cases \[[@r29]\]. There was also concern over the overestimation of stroke diagnosis as the cause of death when there is a history of stroke and a lack of an obvious specific cause of death \[[@r25]\]. In data from the Framingham Study, a high error rate was shown for stroke, including a 40% false negative rate in death certificates, which significantly increased with increasing age at death and increasing interval from the last stroke to death \[[@r30]\]. If death occurred within one month, the frequency of false negatives was 7%, but for those who survived more than one month, it became 59%. Another Swedish study that examined stroke incidence and survival raised concern about underestimation of stroke incidence in previous retrospective studies \[[@r31]\]. They prospectively screened for patients with stroke, using multiple overlapping case ascertainment methods and emphasized the importance of using recommended criteria for an ideal epidemiological stroke study \[[@r32]\]. However, a previous study in Sweden found that the main diagnosis from the patient\'s final hospital discharge record differed from the original underlying cause of death in the death certificate in more than half of all cases \[[@r33]\]. This contradicts other reports on good accuracy of Swedish death certificates \[[@r16]\].

Having stroke in the death certificate and being registered in Riksstroke was associated mostly with the place of death - dying in a hospital was associated with increased odds compared to dying at home or in a nursing home. This can be explained because Riksstroke is by definition a hospital based register, so patients who have a stroke at nursing homes or at home and who are not admitted to hospital will not be included in the register. Stroke is a clinical diagnosis but in order to characterize an event as ischemic or hemorrhagic a CT scan of the brain is needed and this can only be performed in hospitals, making stroke primarily a hospital diagnosis. The current stroke guidelines from the Swedish Board of Health and Welfare accept that some very frail patients with comorbidities or end-of-life stages may not be transferred to the hospital when they suffer a stroke \[[@r34]\]. They recommend that this decision be taken in anticipation of a potential future stroke event, individualized to a particular patient and after discussion with the patient and care providers. However, when patients from nursing homes have received hospital care they are registered in Riksstroke, even if the final place of death is a nursing home. In a recent Swedish study, hospitalization proportions for patients with acute stroke were around 10% lower than previous estimations. 84% of patients were hospitalized with a median duration of 7 days, 8% were examined at a hospital but not hospitalized, 4% were treated within the primary care organization, 1% died before medical examination and 3% had no contact with medical services \[[@r35]\]. Another study analysing late follow-up after stroke (three months to one year), found that 46% of patients died in a nursing home, whereas 37% of patients died in a hospital and 10% of patients died at home, which is a similar distribution compared to our study \[[@r36]\].

4.1. Type of Dementia in Patients who Died from Stroke {#sec4.1}
------------------------------------------------------

As expected from previous work with causes of death in SveDem, we found that most common type of dementia in patients who died from stroke was VD \[[@r10]\]. VD is by definition associated with CVD and therefore patients with VD also have higher prevalence of cardiovascular risk factors \[[@r36]\].

The most common type of dementia in patients who died from other causes was AD. Some studies showed that patients with dementia have an increased risk of stroke \[[@r37]\], others showed that patients with AD did not have an altered risk of ischemic stroke compared to those without dementia, whereas patients with VD had an approximately 2-fold increased risk \[[@r38]\].

Less is known about stroke in other dementia types. In PD, previous studies have shown conflicting results on the relationship between IS and PD. To the best of our knowledge there is little data on stroke mortality in PDD, but stroke-related mortality was estimated to be 1.5 times higher in patients with PD compared to the general population \[[@r39]\]. However, in two case-control studies, the risk of stroke was lower or not different in PD \[[@r40], [@r41]\]. In a study on mortality in PD, 8% of deaths were from cerebrovascular disease \[[@r42]\].

There are also few and conflicting results regarding the relationship between IS and DLB, with studies reporting both increased \[[@r43]\] and decreased risk \[[@r44]\].

There was a lower prevalence of cerebrovascular diseases in FTD compared to patients with non-FTD dementia (12.7% *vs.* 26.1%) but these differences became non-significant after adjusting for age \[[@r45]\].

To conclude, the data on stroke mortality in different types of dementia is still scarce and more research is needed.

4.2. Medications in Patients Dead From Stroke {#sec4.2}
---------------------------------------------

In our study, we found that patients who died from stroke did not differ in the use of antipsychotics, antidepressants, ChEIs, memantine, anxiolytics or hypnotics compared to patients who died from other causes. This is contrary to previous studies showing that patients who were taking anxiolytic and hypnotic drugs presented with significantly increased risk of mortality and higher prevalence of stroke (10% *vs.*7%; P ≤ 0.001) \[[@r46]\]. In recent years, concern has been raised about the increased risk of stroke with the use of antipsychotics, both in general population and patients with dementia \[[@r47], [@r48]\]. The risk of death was about 1.2 to 1.6 times higher compared to the no-treatment group in some studies \[[@r49], [@r50]\]. Because of higher awareness of possible side effects, the use of antipsychotics has been restricted in patients with dementia. A nationwide study from Denmark observed a decrease in the prevalence of antipsychotic use among patients with dementia from 31.3% in 2000 to 20.4% in 2012 \[[@r51]\]. This was accompanied by a decrease in anxiolytics and hypnotics/sedatives, but with an increase in the use of antidepressants from 43.3% in 2000 to 53.8% in 2012 \[[@r51]\]. In comparison, patients in our study used antipsychotics at a lower rate - 6.5% in patients with dementia who died from stroke and registered in Riksstroke compared to 8.1% who died from other causes \[[@r52]\].

4.3. Limitations and Strengths {#sec4.3}
------------------------------

This study is strengthened by a large sample of patients from different health care setting, reflecting the current clinical practice in Sweden, and the utilization of several nationwide registers. The information on causes of death, drugs and comorbidities was derived from nationwide health registers that have a complete coverage in the country. Furthermore, Riksstroke has an excellent coverage in Sweden, containing \> 90% of stroke events in the country \[[@r53]\]. Some limitations need to be mentioned. In the period examined, 52% of memory clinics and 48% of primary care units in Sweden were affiliated to SveDem and patients in SveDem may differ from non-registered patients. It was suggested that patients included in a quality register are more likely to be men, younger, generally healthier and of a higher socioeconomic status \[[@r4]\]. If this holds for SveDem, it may limit the generalizability of our findings to a healthier and younger population that has more contact with health care, possibly leading to an underestimation of the rate of deaths from IS.

Another weakness of this study is the absence of cognitively normal controls. The ascertainment of stroke as the cause of death is obviously a well-founded concern, particularly considering the discrepancies found between stroke as the cause of death and stroke registered in Riksstroke.

This is an observational study, so it is impossible to establish causation between different medications and outcomes.

The validity of the data in SveDem is subject to random cross-checks of histories and entries \[[@r18]\] and less than 5% of dementia diagnoses change during the first year of follow-up \[[@r54]\].

CONCLUSION
==========

Mortality data is a cornerstone of epidemiological research and health monitoring. At both the state and national level, mortality data compiled from death certificates is used to track disease trends, set public health policies, and allocate health and research funding \[[@r55]\]. Quality issues may impact health care policy. The discrepancy between the registration of IS in death certificates and in Riksstroke is a cause for concern. In future, studies on non-dementia patients registered in Riksstroke could determine whether this is a widespread issue or particular of patients with dementia.
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![Medication use at the time of dementia diagnosis.](CAR-15-1322_F1){#F1}

###### Baseline characteristics of patients.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **-**                                                                     **Died from Ischemic Stroke and Registered in**\   **Died from Ischemic Stroke, not in Riksstroke (N=721)**   **Death from Other Causes (N=12990)**   **P Value**
                                                                            **Riksstroke^1^ (N=459)**                                                                                                                             
  ------------------------------------------------------------------------- -------------------------------------------------- ---------------------------------------------------------- --------------------------------------- -------------
  **Place of death**                                                                                                                                                                                                              

  Hospital                                                                  257 (56.0%)                                        121 (16.8%)                                                3266 (25.1%)                            \<0.001†

  Nursing home                                                              182 (39.7%)                                        522 (72.4%)                                                8009 (61.7%)                            

  At Home                                                                   6 (1.3%)                                           30 (4.2%)                                                  705 (5.4%)                              

  Unknown/blank                                                             4 (3.1%)                                           48 (6.7%)                                                  1010 (7.8%)                             

  Age at diagnosis, mean ± SD                                               82.5 ± 6.1                                         82.3± 6.8                                                  81.9 ± 7.2                              0.042‡

  Age at death, mean ± SD                                                   84.5 ± 6.0                                         84.6 ± 6.6                                                 84.3 ± 7.0                              0.434‡

  Female gender, n (%)                                                      274 (59.7%)                                        404 (56.0%)                                                7138 (54.9%)                            \<0.118†

  **Dementia type, n (%)**                                                                                                                                                                                                        

  AD                                                                        90 (19.6%)                                         120 (16.6%)                                                3298 (25.4%)                            \<0.001†

  Mixed                                                                     106 (23.1%)                                        161 (22.3%)                                                2661 (20.5%)                            0.209†

  Vascular                                                                  136 (29.6%)                                        227 (31.5%)                                                2684(20.7%)                             \<0.001†

  DLB                                                                       7 (1.5%)                                           17 (2.4%)                                                  362 (2.8%)                              0.122†

  FTD                                                                       3 (0.7%)                                           5 (0.7%)                                                   188 (1.4%)                              0.096†

  PDD                                                                       4 (0.9%)                                           9 (1.2%)                                                   249 (1.9%)                              0.124†

  Unspecified                                                               106 (23.1%)                                        166 (23.0%)                                                3257 (25.1%)                            0.306†

  Other                                                                     7 (1.5%)                                           16 (2.2%)                                                  289 (2.2%)                              0.604†

  MMSE, median (IQR)                                                        21.0 (7)                                           20.0 (9)                                                   20.0 (9)                                \<0.001

  0 to 17                                                                   155 (33.8%)                                        305 (42.3%)                                                5133 (39.5%)                            0.013†

  18 to 22                                                                  129 (28.1%)                                        238 (33.0%)                                                3962 (30.5%)                            0.860†

  23 and over                                                               175 (38.1%)                                        178 (24.7%)                                                3895 (30.0%)                            \<0.001†

  Total number of drugs, median (IQR)                                       6.0 (5)                                            6.0 (6)                                                    5.0 (5)                                 \<0.001§

  Antidiabetics (A10)                                                       62 (13.5%)                                         107 (14.8%)                                                1454 (11.2%)                            0.004†

  Antithrombotic agents (B01)                                               270 (58.8%)                                        412 (57.1%)                                                5949 (45.8%)                            \<0.001†

  Diuretics (C03)                                                           158 (34.4%)                                        233 (32.3%)                                                3859 (29.7%)                            0.036†

  Beta blocking agents (C07)                                                212 (46.2%)                                        239 (33.1%)                                                4227 (32.5%)                            \<0.001†

  Calcium-channel blockers (C08)                                            79 (17.2%)                                         127 (17.6%)                                                1981 (15.3%)                            0.130†

  Agents acting on the renin-angiotensin system (C09)                       165 (35.9%)                                        231 (32.0%)                                                3476 (26.8%)                            \<0.001†

  Lipid-modifying agents (C10)                                              116 (25.3%)                                        189 (26.2%)                                                2656 (20.4%)                            \<0.001†

  Antipsychotics (N05A)                                                     30 (6.5%)                                          63 (8.7%)                                                  1050 (8.1%)                             0.388†

  Antidepressants (N06A)                                                    108 (27.1%)                                        214 (29.7%)                                                3514 (27.1%)                            0.067†

  Cholinesterase inhibitors (N06DA)                                         157 (35.3%)                                        222 (32.8%)                                                4632 (37.2%)                            0.053†

  Memantine (N06DX01)                                                       43 (9.7%)                                          65 (9.7%)                                                  1300 (10.5%)                            0.665†

  **-**                                                                     **Died from Ischemic Stroke and Registered in**\   **Died from Ischemic Stroke, not in Riksstroke (N=721)**   **Death from Other Causes (N=12990)**   **P Value**
                                                                            **Riksstroke^1^ (N=459)**                                                                                                                             

  Cholinesterase inhibitors in patients with AD or mixed dementia (N06DA)   107 (56.0%)                                        147 (53.8%)                                                3281 (56.0%)                            0.777†

  Anxiolytics (N05B)                                                        55 (12.6%)                                         115 (17.3%)                                                1785 (14.7%)                            0.081†

  Sleeping aids (N05C)                                                      98 (22.5%)                                         151 (22.48%)                                               2497(20.6%)                             0.249†
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^1^Died from ischemic stroke and registered in Riksstroke within the past year. N, number of patients in each category; SD, standard deviation; IQR, interquartile range; MMSE, Mini Mental State Examination score. AD, Alzheimer\'s dementia; mixed, mixed Alzheimer\'s and Vascular dementia; DLB, Dementia with Lewy Bodies; FTD, Frontotemporal dementia; PDD, Parkinson\'s disease with dementia. P-values obtained from †Chi-Square, ‡ANOVA with Welch test because of non-homogenous variances, § Kruskal-Wallis.

###### Comorbidities at dementia diagnosis.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  \-                                        **Died from Ischemic Stroke and Registered in Riksstroke (N=459)**   **Died from Ischemic Stroke, not in**\   **Death from Other Causes (N=12990)**   **P Value**
                                                                                                                 **Riksstroke (n=721)**                                                           
  ----------------------------------------- -------------------------------------------------------------------- ---------------------------------------- --------------------------------------- -------------
  **Comorbidities at dementia diagnosis**                                                                                                                                                         

  Diabetes mellitus, n (%)                  88 (19.2)                                                            140 (19.4)                               2046 (15.8)                             0.006

  Arterial hypertension, n (%)              265 (57.7)                                                           371 (51.5)                               5705 (43.9)                             \<0.001

  Anemia                                    34 (7.4)                                                             38 (5.3)                                 839 (6.5)                               0.308

  Liver disease, n (%)                      2 (0.3)                                                              4 (0.9)                                  147 (1.1)                               0.088

  Kidney disease, n (%)                     43 (9.4)                                                             49 (6.8)                                 1074 (8.3)                              0.250

  Heart failure, n (%)                      102 (17.4)                                                           122(16.9)                                2264 (17.4)                             0.027

  Atrial fibrillation, n (%)                191 (41.6)                                                           193 (26.8)                               2859 (22.0)                             \<0.001

  Previous femur fracture, n (%)            50 (10.9)                                                            90 (12.5)                                1435 (11.0)                             0.485

  Previous stroke, any type n (%)           155 (33.8)                                                           291 (40.4)                               2437 (18.8)                             \<0.001
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^1^Died from ischemic stroke and registered in Riksstroke within the past year. Any type stroke refers to both ischemic and hemorrhagic. P values obtained from Chi-Square tests.

###### Odds ratios (OR) of having ischemic stroke (IS) and a Riksstroke registration in the death certificate, relative to place of death.

  **-**          **OR for having IS (95% CI)**   **OR for being Registered in Riksstroke (95% CI)**
  -------------- ------------------------------- ----------------------------------------------------
  Hospital       Ref.                            Ref.
  Nursing home   0.80 (0.69-0.92)\*\*\*          0.17 (0.12-0.22)\*\*\*
  At Home        0.49 (0.34-0.70)\*\*\*          0.09 (0.04-0.23)\*\*\*

Logistic regression was used to assess the association of place of death (hospital, nursing home or at home) with IS in the death certificate and of having a Riksstroke registration within the year prior to death. Adjusted for age, sex, number of medication, Mini-Mental State Examination (MMSE), dementia type, previous diagnosis of diabetes, hypertension, heart failure, atrial fibrillation, stroke, anemia, hip fracture, liver diseases and kidney diseases. Adjusted odds ratios (ORs) with 95% confidence intervals (CIs) are presented. \* P ≤ 0.05; \*\* P ≤ 0.01; \*\*\* P ≤ 0.001.
